Navigation Links
Nexavar in Combination with Chemotherapy Shown to Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Date:7/22/2009

ug. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward Looking Statements This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer Web site at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release also contains "forward-looking statements" of Onyx within the meaning of the federal securities laws. These forward-looking statements include without limitation, statements regarding timing, progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Nexavar. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2008, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. Onyx undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

Nexavar(R) (sorafenib) tablets is a registered trademark of Bayer H
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
2. New Analyses Confirm Nexavars Efficacy and Safety in Multiple Patient Subsets With Liver Cancer
3. Nexavar Approved in Japan for the Treatment of Advanced Liver Cancer
4. Phase 3 Trial Initiated to Evaluate Combination Therapy of Nexavar(R) and Tarceva(R) in Patients with Liver Cancer
5. Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
6. Promising drug combination may help those with ocular melanoma that has spread
7. Combination therapy reverses effects of portal hypertension in rats
8. Combination vaccines okay for infants, study shows
9. Antidepressants and painkillers - a dangerous combination
10. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
11. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota (Blue ... means to “Live Fearless.” , The “Faces of ... stories about how they or someone they know has faced ... in the moment. By telling these types of stories through ...
(Date:1/22/2015)... Orlando, Florida (PRWEB) January 22, 2015 ... up today at the 2015 PGA Merchandise Show to ... lady and incredible female amateur golfer, Arlene McKitrick. The ... career female amateur golf tournament win. She won her ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post explaining ... policy . , Auto insurance quotes help many drivers ... longer necessary to call an agent or visit an agency ... a single website: http://autocarinsurancebest.com/ . , Every business who ...
(Date:1/22/2015)... 2015 Joan Lunden, award-winning American journalist, ... the upcoming 32nd Annual Miami Breast Cancer Conference ... Resource®, LLC (PER®) , shares that “a fast-growing, virulent” ... if she had not followed up her clean mammogram ...
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2
... job of communicating critical elements of medication use when they ... has found//. ,The study, slated for publication in the ... that in too many instances, physicians did not address such ... effects or even the names of drugs they were prescribing ...
... of Technology are proposing a revolutionary approach to ... (re-clogging of coronary arteries). ,More than 1.2 ... in 2003, according to the American Heart Association. ... during which a tiny deflated balloon is inserted ...
... Washington: A finding by the advocacy group, Families USA, suggests ... have at least one parent employed full-time//. And in 25% ... members. ,The group's executive director, Ron Pollack said ... work, who are very different from themselves. These are people ...
... with Simcere Pharmaceutical Group of Nanjing, China for it ... flu drug Relenza in poor countries//. ,The ... Indonesia, Thailand, Vietnam and all least-developed countries, under the ... everything we can to prepare for a global influenza ...
... California, San Diego and Yale University have discovered that ... sprayed// on crops by organic farmers to reduce insect ... laboratory animals. ,Their discovery, detailed in this week’s ... Academy of Sciences, could pave the way for the ...
... therapy with statin medications reduces death and cardiovascular ... or other acute heart events//, according to an ... levels, have clearly been shown to benefit patients ... the article. However, it is less clear whether ...
Cached Medicine News:Health News:Physician Communication Spotty When Prescribing Medications 2Health News:Novel Technique Would Prevent Re-Clogged Arteries 2Health News:Bacterial Protein Shows Promise in Treating Intestinal Parasites 2Health News:Bacterial Protein Shows Promise in Treating Intestinal Parasites 3Health News:Early Statin Therapy for Patients Reduces Death, Cardiovascular Events 2
(Date:1/23/2015)... Jan. 23, 2015  Today the U.S. Food and Drug ... the prevention of serogroup B meningococcal disease ... vaccine Trumenba®, which received FDA approval in October, represent ... disease. "I have heard over and ...
(Date:1/23/2015)... , Jan. 23, 2015  The Partnership to Fight Chronic Disease ... health care leaders and a new study analyzing the impact ... PFCD is a nationwide coalition working to educate policy makers and ... at the Capitol was focused on how the Iowa ...
(Date:1/23/2015)... 23, 2015 More than a third of reproductive-aged women ... with private insurance, filled a prescription for an opioid pain ... this week,s Morbidity and Mortality Weekly Report (MMWR). ... treat moderate to severe pain.  They are also found in ...
Breaking Medicine Technology:The National Meningitis Association (NMA) Applauds FDA Approval of Second Vaccine To Protect Against Serogroup B Meningococcal Disease 2New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... hold its annual meeting of stockholders on Wednesday, June 9, 2010 at 9:00a.m. Pacific Time for all stockholders of record on ... ... , , ... ...
... the Barclays 2010 Global Healthcare Conference on March 23, 2010 at 1:30 p.m. eastern at the Loews Hotel in Miami, Florida . , ... , ... ... ...
Cached Medicine Technology:PDL BioPharma To Hold Annual Meeting of Stockholders on June 9, 2010 2Express Scripts to Present at Barclays 2010 Global Healthcare Conference 2
... Cytometry Concentrate is for use as a ... cytometry. Each 70ml bottle of Cytometry Concentrate ... distilled water. Compared to Cubitainers, Streck Cytometry ... and saves money without compromising performance. Streck ...
... CD34 is a stabilized preparation ... can be used as a ... CD34 positive cells. It is ... ProCOUNT gating strategies. CD-Chex CD34 ...
... A lytic reagent manufactured ... determination of hemoglobin and ... Agent IIIA is manufactured ... the Abbott CELL-DYN® 1700. ...
Streck-Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3000. The shelf life is two years from the date of manufacture....
Medicine Products: